PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
about
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.Systems biology approaches to develop innovative strategies for lung cancer therapy.Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancerRedesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
P2860
Q33426444-271FA53C-C6AD-41C6-9BC5-FE92915F7C54Q33435557-DF74C782-C100-462A-A1CF-96402B14301BQ33720233-83D53E2E-1AF7-424D-8518-7931AD67BBC0Q34502009-BB4840E7-C7DB-40F5-93AC-BF0127E555E2Q34572581-786AD8DF-59BB-4135-8F8A-96A4AF24A275Q37185747-8B45A651-3652-4114-888D-9E006C9D7DD6Q37521242-875AB85C-AA97-46B1-AB87-FD299F271064Q38697331-66924AC3-F596-458F-8BF1-8CAD8BB5D154Q38740969-E8C73F71-9933-4D08-947A-194182AE30FEQ41276800-ADC7EDA9-FBA1-4452-A1D9-DA43B8A5442FQ53817080-E723446B-9B6B-463D-B805-D86923876B41Q55504427-3DAEF5AC-372A-46B4-80CC-6CA2BF854937
P2860
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@en
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@nl
type
label
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@en
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@nl
prefLabel
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@en
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@nl
P2093
P50
P1433
P1476
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
@en
P2093
Angélique Robin
Elsa Vanhecke
Fréderic Commo
Helmut Popper
Julien Adam
Jürgen Thomale
Ken A Olaussen
Louis Kayitalire
Luc Friboulet
Martin Filipits
P304
P356
10.1016/J.LUNGCAN.2013.01.014
P577
2013-02-12T00:00:00Z